Sidestepping SHP2 inhibition.

Published in: The Journal of experimental medicine (2023)

Allosteric SHP2 inhibitors are a novel class of compounds that target hyperactive Ras/Mitogen Activated Protein Kinase (MAPK) signaling. In this issue of JEM, Wei et al. (2023. J. Exp. Med.https://doi.org/10.1084/jem.20221563) report a genome-wide CRISPR/Cas9 knockout screen that uncovered novel mechanisms of adaptive resistance to pharmacologic inhibition of SHP2.

Keyphrases

crispr cas
genome wide
genome editing
dna methylation
small molecule
signaling pathway
oxidative stress
high throughput
wild type
gene expression
protein kinase
copy number